COL4A5 and Alport syndrome: To determine the molecular effects of metformin and losartan on Alport syndrome, we assessed the global mRNA expression profile in kidney tissues of WT and Col4a5 G5X Alport syndrome mice treated with vehicle, metformin, or losartan for 10 weeks.